

# **National Institutes of Health Management**

## **House Appropriations Subcommittee on Labor/HHS/Education**

**Elias A. Zerhouni, M.D.  
Director, National Institutes of Health**


**Allen M. Spiegel, M.D., Director, National Institute  
of Diabetes and Digestive and Kidney Diseases**

**Story C. Landis, Ph.D., Director, National  
Institute of Neurological Disorders and Stroke**

**April 22, 2004**



# New NIH Decision-making Process



# Innovations in NIH Management

- **Administrative Restructurings Underway:**

Acquisitions, Finance, Budget, Grants Management, Facilities, Equal Employment Opportunity, Information Technology, Human Resources

- **Enterprise Systems Being Implemented:**


Grants Applications and Awards Management (eRA), Finance and Business Support (NBS), Human Resources (EHRP), Clinical Research Information (CRIS)

- **Future Directions:**

Data Mining for Disease Funding Tracking  
Leadership Development for Scientific and Administrative Positions

# MANAGEMENT EXCELLENCE AND STEWARDSHIP

% Increases in Funding and FTEs over FY 1996 Levels




# Completion of the Mark O. Hatfield Clinical Research Center

- Largest hospital in the world totally dedicated to clinical research
- Center for the largest number of patients with orphan (rare) diseases in the world
- Provides working environment with unparalleled confluence of basic and clinical researchers and with “Bench to Bedside” literally a few steps down the hall
- Nation’s major training center for clinical investigators
- Occupancy – Fall 2004



# Effective Portfolio Management



# NIH Portfolio Management and Priority Setting

## *Factors in Resource Allocation Decisions*

### *Examples:*

- Public Health Needs
- Scientific Opportunities
- Scientific Merit
- Stakeholder Input
  - *patient groups, research community*

# Portfolio Management, cont.


## *Proactive Management Steps*


### *Examples:*

- Strategic and Operational Planning
- Scientific Conferences, Workshops
  - *multi-IC; multidisciplinary*
- Research Solicitations
  - *RFAs, PAs, Contracts*
- New Mechanisms for Supporting Synergistic Research
  - *Consortia, Networks*
- Peer-Review
  - *Study Section and Nat'l Advisory Council*
- Ongoing Evaluation
  - *scientific pubs.; disease trends*

# Strategic Planning Efforts To Guide NIDDK Priority Setting

## Examples





# Polycystic Kidney Disease (PKD)

## *Portfolio Management*

Renal Disease Research Plan  
PKD Centers  
PKD Imaging Consortium

Meeting: Strategic Planning for  
Polycystic Kidney Disease

HALT-PKD trial



1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

PKD1 and PKD2 genes found

PKD proteins' function  
And location

Candidate Rx for  
PKD


## *Scientific Discoveries*

# Obesity

## Portfolio Management

Draft Strategic Plan for NIH Obesity Research posted for comments

Obesity/Nutrition Research Centers established (92)




NIH Obesity Research Task Force established



## Scientific Discoveries

# Consortium of Neuroscience Institutes



•NINDS

•NIMH

•NIDCD

•NEI

•NIDA

•NIAAA

•NIA


•NIDCR

•NICHD


**BLUEPRINT FOR THE BRAIN:**

**Tools, Technologies, and Training**


# Parkinson's Disease Research Agenda



# NIH CENTERS and NET-PD SITES



# Planning Matrix



# NIH Obesity Research Matrix

High risk

0 – 3 yrs

4 – 6 yrs

7 – 10 yrs

<ul style="list-style-type: none"> <li>● Identify novel biomarkers that are associated with obesity related co-morbidities using genomic or proteomic approaches across diverse racial and ethnic groups</li> <li>● Improve public awareness of the effects of overweight on disease risk and quality of life (Public Outreach)</li> <li>● Use model organisms to identify novel pathways or molecules involved in regulation of body composition, food consumption, or physical activity levels</li> </ul>	<ul style="list-style-type: none"> <li>●●● In well characterized clinical trial populations, test the of novel biomarkers to predict therapeutic efficacy or the progression of co-morbidities associated with obesity</li> <li>● Identify the relative contributions of various sociocultural, environmental, and behavioral factors to obesity development in adults and children</li> <li>● Identify genes associated with increased or decreased risk for obesity in metabolically well characterized populations from diverse racial and ethnic groups</li> <li>● Develop and test strategies to maintain healthy weight in children and adults through behavior (activity, diet) change which can be applied in a home, school, or workplace environment</li> </ul>	<ul style="list-style-type: none"> <li>● Evaluate the effectiveness and assure translation of strategies to maintain healthy weight in children and adults through behavior (activity, diet) change which can be applied in a home, school, or workplace environment</li> <li>● Use knowledge of regulation of energy storage and food intake to develop new therapeutic modalities (including drugs, surgery, and other technologies) to complement lifestyle interventions</li> <li>● Use knowledge of mechanisms whereby obesity increases risk for co-morbidities to develop potential therapeutic approaches for ameliorating these conditions independent of weight loss</li> </ul>
<ul style="list-style-type: none"> <li>● Identify potential cost-effective approaches to modifying environments and policies to support increased physical activity, improved dietary practices, and weight control in children and adults</li> <li>● Partner with other governmental agencies (local, state, national) to translate successful healthy weight control strategies to practice</li> <li>● Establish periodic surveys of health care providers treating children and adults to evaluate knowledge, attitudes and behaviors related to weight control in clinical practice</li> <li>● Establish guidelines for collection of data and samples that would encourage the assessment of multiple co-morbidities within diverse populations</li> </ul>	<ul style="list-style-type: none"> <li>●●● Develop improved technologies, including e-technologies, for the assessment of and as intervention tools related to dietary intake, physical activity</li> <li>● Determine the relationship between inflammatory markers and obesity</li> <li>●●● Determine the relationship between mental disorders and the development of obesity or ability to achieve and maintain a healthy weight</li> <li>● Define the brain regulatory pathways that control food intake and energy metabolism and identify the effects of caloric restriction and increased energy expenditure on energy metabolism, brain regulatory pathways, and body composition</li> </ul>	<ul style="list-style-type: none"> <li>● Identify genetic variants that affect risk of development of co-morbidities, and determine the frequency and population risk in diverse populations</li> <li>●●● Identify aspects of differential fat distribution or longitudinal patterns of weight change that are associated with greatest health risk in diverse populations</li> <li>●● Determine frequency and population risk of obesities associated with identified genetic variants</li> <li>●● Elucidate the role of dietary macronutrient and micronutrient composition on energy metabolism, brain regulatory pathways, appetite, and body composition in humans</li> </ul>
<p>Low risk</p> <ul style="list-style-type: none"> <li>●●● Identify areas where the lack of technology or resources are limiting research progress such as tools to measure energy balance in humans</li> <li>● Determine age, sex, and race/ethnicity specific estimates of physical activity, dietary intake, and body composition in the US population</li> <li>● Incorporate the evaluation of public comprehension of public health recommendations in the areas of physical activity, diet and weight control as well as assessment of current weight control/weight loss practices into national and regional health surveys</li> </ul>	<ul style="list-style-type: none"> <li>● Determine the long-term effects of exercise on body composition and obesity-associated health risk independent of weight change</li> <li>● Partner with private and public organizations involved in health care delivery to identify best practices and consider effective policies and approaches to facilitate translation into clinical care and community settings</li> <li>●● Elucidate the role of dietary macronutrient and micronutrient composition on energy metabolism, brain regulatory pathways, appetite, and body composition in animal models</li> </ul>	<ul style="list-style-type: none"> <li>●● Use weight loss models (e.g., diet, surgery, physical activity) to understand the biological and psychological factors contributing to weight regain in humans</li> <li>● Use prospective observational studies to identify behavioral and environmental determinants of excessive weight gain and obesity in children and adolescents</li> <li>● Determine the effects of nutritional/environmental factors at critical periods throughout life such as fetal, neonatal, adolescence, during pregnancy, menopause, and in older adulthood on the central and peripheral nervous system</li> </ul>

# Effective Portfolio Management

